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Abstract: Voriconazole plasma concentrations (PC) are highly variable, particularly in children. Dose
recommendations in 2–12-year-old patients changed in 2012. Little data on therapeutic drug moni-
toring (TDM) after these new recommendations are available. We aimed to evaluate voriconazole
monitoring in children with invasive fungal infection (IFI) after implementation of new dosages and
its relationship with safety and effectiveness. A prospective, observational study, including children
aged 2–12 years, was conducted. TDM was performed weekly and doses were changed according to
an in-house protocol. Effectiveness, adverse events, and factors influencing PC were analysed. A total
of 229 PC from 28 IFI episodes were obtained. New dosing led to a higher rate of adequate PC com-
pared to previous studies; still, 35.8% were outside the therapeutic range. In patients aged < 8 years,
doses to achieve therapeutic levels were higher than recommended. Severe hypoalbuminemia and
markedly elevated C-reactive protein were related to inadequate PC. Therapeutic PC were associated
with drug effectiveness and safety. Higher doses in younger patients and a dose adjustment protocol
based on TDM should be considered. Voriconazole PC variability has decreased with current updated
recommendations, but it remains high and is influenced by inflammatory status. Additional efforts
to control inflammation in children with IFI should be encouraged.
Keywords: paediatric fungal infections; antifungal treatment; therapeutic drug monitoring; voriconazole;
children; inflammation
1. Introduction
Invasive fungal infection (IFI) is an uncommon condition, occurring almost exclusively
in immunosuppressed and critically ill patients. It is associated with high morbidity and
mortality, especially when caused by filamentous fungi [1–6]. Management of IFI in children
requires considerable expertise, and the appropriate diagnosis and treatment can determine
the course of the disease. Approved in 2002 by the FDA, voriconazole is a broad-spectrum
triazole antifungal agent that has become a mainstay of both primary and salvage treatment
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for invasive aspergillosis and candidiasis [1,7–14]. Several publications, mainly in adults but
also in children, suggest that therapeutic drug monitoring (TDM) improves the efficacy and
safety of voriconazole [1,8,15–24]. As between-subject differences in voriconazole plasma
concentrations (PC) are more marked in children than in adults [25–30], monitoring of trough
concentrations is particularly important in children to ensure optimal treatment.
In 2011, our group reported a relationship between sub-therapeutic voriconazole
concentrations and lower treatment effectiveness in paediatric patients, and between supra-
therapeutic concentrations and neurological and skin toxicity. In addition, we suggested
the need to increase dosage in younger patients to achieve appropriate PC [17]. In 2012,
based on a pharmacokinetic study by Friberg et al. [31], the recommended voriconazole
dose was changed in patients aged 2 to 12 years, with an increase in the maintenance
dose to 16 mg/kg/day. Since that time, only a small number of studies have evaluated
voriconazole monitoring in children according to the new recommendations, and most
are in Asian populations [32–34]. The aim of this study was to assess the variability of
plasma voriconazole in children receiving the drug according to the current posology for
treating IFI. The secondary aim was to determine the overall effectiveness and safety of
voriconazole treatment and investigate relationships between these aspects and the drug
monitoring findings.
The findings of this study indicate that variability of voriconazole remains high despite
the 2012 updated dosing recommendations, and that drug levels are influenced by severe
hypoalbuminemia and elevated C-reactive protein (CRP). Voriconazole at appropriate
doses is effective and safe in children, and PC are related to treatment effectiveness and
safety in children with IFI. Nonetheless, higher voriconazole doses should be considered
in patients below 8 years old, and standardized recommendations for dose adjustment
should be designed based on monitoring results.
2. Materials and Methods
This prospective study was conducted at Vall d’Hebron Children’s Hospital, a tertiary-
care referral centre in Barcelona (Catalonia, Spain) with an average of 7500 hospitalizations
per year and a dedicated paediatric cancer and hematopoietic stem cell transplantation
(HSCT) department. Around 250 paediatric cancer patients are treated and 40 HSCT
procedures are performed per year in our centre.
2.1. Ethics
The study was approved by the local ethics committee (EPA (AMI) 69/2013 (3874)). All
procedures were in accordance with the 1964 Helsinki declaration and its later amendments.
Informed consent was obtained from the legal representatives of all participating patients.
2.2. Inclusion Criteria
The study included consecutive patients aged 2 to 12 years and weighing less than
50 kg, who had received medical care at our centre from January 2014 to August 2018 due
to proven, probable, or possible IFI, established according to the diagnostic criteria of the
European Organization for Research and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses
Study Group (EORTC/MSG) Consensus Group [35]. In 2019, the EORTC/MSG definitions
were updated [36], but the update was not used in the present study, as data collection
ended in 2018. Patients were required to have received voriconazole as treatment for IFI
with the 2012 recommended dosage according to the datasheet for this age group.
2.3. Procedures
Intravenous voriconazole administration consisted of an initial loading dose of 9 mg/kg
q12h in the first 24 h followed by a maintenance dose of 8 mg/kg q12h. Oral administration
used a dose of 9 mg/kg q12h without a loading dose.
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Voriconazole trough levels were determined within the first week of treatment and
weekly thereafter using a Shimadzu Nexera HPLC system with a fluorescence detector for
antifungals [37,38]. The lower limit of quantification, defined as the minimum voriconazole
concentration measured in plasma with an accuracy of around 5%, was 0.3 mg/L. Values
below this limit were recorded as <0.3 mg/L. Voriconazole concentrations of 1 to 5.5 mg/L
(both values included) were considered adequate regardless of the location of the infection.
When voriconazole levels were outside the desired therapeutic range, a dose adjust-
ment recommendation was determined following the local protocol used in the study:
at values <1 mg/L, a 50% daily dose increase was recommended; at values >5.5 mg/L,
voriconazole was discontinued for 24 h, followed by a 50% daily dose decrease. When
adverse events (AEs) attributable to voriconazole were considered relevant by the attend-
ing clinician, voriconazole was stopped until PC dropped to within the desired range and
AEs were considered controlled; voriconazole was then reinitiated with a 50% decrease in
daily dose.
2.4. Data Collection and Definitions
Epidemiological and clinical data, complementary examinations, relevant co-medications
in terms of interactions, and concomitant antifungal medication were recorded. Follow-up
continued throughout the treatment period (including maintenance treatment) up to at
least 6 months after the start of voriconazole in surviving patients. At least 2 treatment
response evaluations were performed (early and late evaluation) in accordance with the
EORTC/MSG treatment response criteria [39]. Complete and partial response were defined
as successful treatment and any other situation was defined as treatment failure, including
deaths that were not attributable to IFI.
AEs were classified according to the Common Terminology Criteria for Adverse
Events v5.0 (U.S. Department of Health and Human Services, National Institutes of Health,
National Cancer Institute) [40]. Abnormalities detected during treatment that were not
present before starting treatment, and those that were present and worsened during
treatment were considered as possibly related to voriconazole.
2.5. Statistical Analysis
Several statistical tests were carried out to analyse relationships between plasma
voriconazole concentrations and the study variables. Descriptive statistics were used to
summarize data related to the patients, IFI episodes and adverse events: the median and
interquartile range (IQR) for quantitative variables and the frequency for qualitative ones.
The chi-square test or likelihood ratio test, as appropriate, were performed for qualitative
variables. The Student’s t-test (or ANOVA) or the Wilcoxon test (or Kruskal–Wallis test), as
appropriate, were conducted for quantitative variables. The Pearson correlation coefficient
was used to study relationships between two quantitative variables.
Only proven or probable IFI episodes were included in the analysis of treatment
effectiveness, whereas data from all IFI episodes were included in the safety analysis.
Considering the dichotomous nature of the secondary dependent variables—treatment
effectiveness (success or failure), AEs (presence or absence), and plasma voriconazole value
(≤5.5 mg/L or >5.5 mg/L)—three multivariate logistic models (MLM) were developed,
including all covariates in the models. Voriconazole values were categorized into three
levels: sub-therapeutic, therapeutic, and supra-therapeutic. In this case, a multinomial
model was used. In all models, a backward procedure was applied to eliminate covariates
from the analysis based on statistical criteria.
Finally, a cut-off point was established to form two groups (<8 y and ≥8 y), using
the age at which significant differences were seen in the dose administered to achieve
correct PC. To analyse the effect of dose on the voriconazole level, a repeated measures
analysis using a linear mixed-effects model (LMM) was applied in each group: patients
were considered random factors and the various dose determinations were the within-
subject repeated measures. For this analysis, we excluded patients receiving medication
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that could significantly change voriconazole concentrations according to the datasheet:
carbamazepine, phenobarbital, efavirenz, rifabutin, rifampicin, ritonavir, St. John’s wort,
fluconazole, and phenytoin.
The statistical analysis was performed using the SAS System v9.4 (SAS Institute
Inc., Cary, NC, USA). A nominal significance level of 5% (p < 0.05) was applied in all
statistical tests.
3. Results
3.1. Characteristics of Patients and Invasive Fungal Infections
Twenty-seven patients were included, 55% male and a median age of 9 years (IQR 6–10 y).
Most patients (85.2%) were non-Asian and mainly white Europeans (59%) (Table 1). The
number of patients in each ethnic group was not large enough to evaluate potential differ-
ences according to ethnicity. Overall, 28 IFI episodes were recorded (18 proven/probable)
with the predominant cause being filamentous fungi, particularly Aspergillus spp. The lung
was the most commonly affected site, followed by the cranial sinus and central nervous
system; a total of 28.6% of patients had disseminated disease (Table 2). The median du-
ration of voriconazole treatment in patients with proven or probable IFI was 80.5 days
(IQR 15–117 days). Although a dual antifungal regimen (voriconazole plus liposomal am-
photericin B) was used at some point to treat 12 of the 18 episodes of proven/probable IFI,
the median duration of this treatment was 27.5 days (12.8–64.3), approximately one-third
the total duration of voriconazole treatment (Table 2).
Table 1. Baseline patient characteristics.
N (%) or Median (IQR)
Patients 27
Age, y 9 (6–10)








South American 3 (11.1)
Sub-Saharan 1 (3.7)
Underlying diseases




















Abbreviations: ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; CMV, cytomegalovirus;
GVHD, graft-versus-host disease; HSCT, haematopoietic stem cell transplantation; IFI, invasive fungal infection;
MDS, myelodysplastic syndrome; PID, primary immunodeficiencies. a—4 chronic granulomatous disease,
3 severe combined immunodeficiency, 1 hyper-IgM syndrome. b—3 medullary aplasia, 1 major thalassemia,
1 Fanconi anaemia.
J. Fungi 2021, 7, 456 5 of 17
Table 2. Characteristics of proven or probable IFI episodes.
N (%) or Median
(IQR)
Episodes of proven or probable IFI a 18
Microorganism
Moulds
Aspergillus spp. b 13 (72.2)
Cladosporium
cladosporioides 1 (5.6)
Fusarium solani 1 (5.6)
Yeasts
Candida spp. c 2 (11.1)
Trichosporon asahii 1 (5.6)
Affected sites d
Disseminated d 6 (33)
Lung 13 (72.2)






Heart (endocarditis) 2 (11.1)
Other sites (8 cases) e 1 (5.6)
Type of treatment
Primary 10 (55.6)
Salvage treatment 5 (27.8)
Suppressive treatment f 3 (16.7)
Duration of voriconazole treatment, days 80.5 (15–117)
Dual antifungal therapy at some point in the episode 12 (66.7)
Duration of dual antifungal treatment, days 27.5 (12.8–64.3)
Surgery 10 (55.6)
Abbreviations: CNS, central nervous system; IFI, invasive fungal infection. a—Based on the diagnostic criteria
of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group.
b—3 A. fumigatus, 2 A. flavus, 1 A. nidulans, 4 Aspergillus sp. (unidentified Aspergillus isolates), 5 probable As-
pergillus spp. (clinical suspicion and positive serum galactomannan test). c—1 C. albicans, 1 C. krusei, 1 C. lusitaniae.
d—6 episodes involved more than 1 site. e—Bone, skin and mucosa with angioinvasion, eyes, liver, retropharyn-
geal abscess, venous thrombosis and neck soft tissue. f—Antifungal therapy once the acute phase is over and
clinical stability is verified.
3.2. Therapeutic Drug Monitoring
Two hundred and twenty-nine voriconazole determinations were analysed (Table 3),
and 64.2% were within the therapeutic range. Among those outside the range (35.8%),
27.5% were sub-therapeutic and 8.3% supra-therapeutic. The percentage of sub-therapeutic
levels during the first week of treatment (43.5%) was higher than in the remainder of the
treatment period (25.9%), but the difference was not statistically significant (chi-square,
3.21; p = 0.07).
Dose changes corrected 63% of determinations outside the therapeutic range. This
percentage rose to 75% when the protocolled dose adjustment recommendations were
strictly adhered to, although the difference was not statistically significant (chi-square, 2.38;
p = 0.12).
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Table 3. Analysis of plasma voriconazole levels during treatment.
Plasma Voriconazole Levels
p
<1 mg/L 1–5.5 mg/L >5.5 mg/L
Determinations, n (%) 63 (27.5) 147 (64.2) 19 (8.3) -






IV, n (%) 41 (29.1) 87 (61.7) 13 (9.2)
NS
Oral, n (%) 22 (25) 60 (68.2) 6 (6.8)
Concomitant omeprazole
administration
No, n (%) 7 (22.6) 20 (64.5) 4 (12.9)
NS
Yes, n (%) 56 (28.3) 127 (64.1) 15 (7.6)
CRP b
≤4 mg/dL, n (%) 31 (23.3) 92 (69.2) 10 (7.5)
NS
>4 mg/dL, n (%) 26 (34.2) 41 (54) 9 (11.8)
Plasma albumin
>3.4 mg/dL, n (%) 28 (23.5) 83 (69.8) 8 (6.7)
0.023–3.4 mg/dL, n (%) 21 (30.4) 45 (65.2) 3 (4.4)
<3 mg/dL, n (%) 14 (34.2) 19 (46.3) 8 (19.5)
Statistical inference using the chi-square test. Abbreviations: CRP, C-reactive protein; IV, intravenous; NS, not significant. a—Average dose
administered taking into account changes in the initial dosage depending on plasma values of the drug. b—Available in 209/229 determinations.
To achieve therapeutic concentrations, the estimated average dose was significantly
higher in patients <8 years than in those ≥8 years (21 vs. 16.5 mg/kg/day; LMM, F = 5.16;
p = 0.02). A significant effect of the dose administered on the voriconazole concentration
was observed in the younger group (LMM, F = 4.79; p = 0.01): a dose increase of one unit
increased the plasma concentration by 0.08 units.
Regarding factors that could potentially affect voriconazole levels, no differences were
found in association with the administration route or concomitant omeprazole adminis-
tration. However, statistically significant differences were observed when albumin was
<3 mg/dL (chi-square, 12.04; p = 0.02) (Table 3).
In addition, this analysis was performed after grouping the voriconazole levels into
two categories (therapeutic and non-therapeutic). In this case, CRP values ≥ 4 mg/dL
(chi-square, 4.85; p = 0.03) and albumin < 3 mg/dL (chi-square, 7.31; p = 0.03) were both
significantly associated with inadequate PC (Table 4).
Table 4. Relationship between adequate voriconazole level and CRP and albumin status.
Plasma Voriconazole Levels
p
Overall Non-Therapeutic(<1 mg/L; >5.5 mg/L)
Therapeutic
(1–5.5 mg/L)
Determinations, n (%) 229 82 (35.8) 147 (64.2) -
CRP a
≤4 mg/dL 133 (63.6) 41 (30.8) 92 (69.2)
0.03
>4 mg/dL 76 (36.4) 35 (46) 41 (54)
Plasma albumin
>3.4 mg/dL 119 (52) 36 (30.3) 83 (69.7)
0.033–3.4 mg/dL 69 (30.1) 24 (34.8) 45 (65.2)
<3 mg/dL 41 (17.9) 22 (53.7) 19 (46.3)
Statistical inference using the chi-square test. Abbreviations: CRP, C-reactive protein. a—Available in 209/229 determinations.
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3.3. Effectiveness
Treatment effectiveness in the early evaluation was 60%. This value increased to 73.3%
when stabilized filamentous IFI in a severely immunosuppressed patient was considered
a treatment success, as is suggested in the EORTC/MSG treatment response criteria [39].
Treatment effectiveness in the late evaluation was 53%. When the late assessment included
a 6-month evaluation in patients receiving salvage treatment for IFI due to filamentous
fungi, the overall late effectiveness rate rose to 60%. No breakthrough infections occurred
during the study period. Six-month survival was 80%, and no deaths were attributed to IFI
(Table 5).
Table 5. Response to treatment in proven or probable IFI episodes.
Response to Treatment a, n = 15 b
Early evaluation
(4–6 weeks) c
Success, n (%) 9 (60)
Complete response 3 (20)
Partial response 6 (40)
Failure, n (%) 6 (40)
Stable disease 4 (26.7)




Success, n (%) 8 (53.3)
Complete response 5 (33.3)
Partial response 3 (20)
Failure, n (%) 7 (46.7)
Stable disease 1 (6.7)
Progression of IFI 4 (26.7)
Death 2 (13.3)
Survival at 6 months, n (%) 12 (80)
Death attributed to IFI/death due to any cause at 6 months, n/n 0/3 d
Follow-up, median (IQR) 326 days (177–614.5)
Abbreviations: IFI, invasive fungal infection. a—Response to therapy according to the consensus criteria of the
Mycoses Study Group and European Organization for Research and Treatment of Cancer. b—Episodes in which
voriconazole was used as a suppressive treatment are not included in the effectiveness analysis. c—4 weeks in
yeast infection; 6 weeks in mould infection. d—Progression of underlying disease.
In the early evaluation, the presence of graft-versus-host disease (chi-square, 6.96;
p < 0.01) and use of dual antifungal therapy (chi-square, 5.04; p = 0.02) were both associated
with a poorer disease course. The late evaluation revealed a significant relationship between
voriconazole levels ≥1 mg/L and treatment effectiveness (chi-square, 7.16; p = 0.03).
3.4. Safety
Liver enzyme abnormalities were the most common AEs (24/27 patients), with in-
creases in gamma glutamyl transferase (GGT) values predominating over alanine amino-
transferase (ALT), total bilirubin (TBIL), or alkaline phosphatase (ALP) changes. However,
most AEs were not severe (grade < 3), had no clinical impact, and reversed at completion of
treatment. Non-hepatic AEs were much less common, and all were grade one or two. These
included gastrointestinal, neurological, or cutaneous AEs (2 of each in the 27 patients) and
visual or renal AEs (1 of each in the 27 patients) (Table 6). Voriconazole withdrawal was
required in two AEs (7.1%): one case of photosensitivity and another of gastrointestinal
intolerance to oral voriconazole.
A statistically significant relationship was observed between supra-therapeutic voricona-
zole concentrations and abnormally increased ALP levels (chi-square, 5.91; p = 0.02).
Although TBIL and GGT elevations were also more frequent at high voriconazole levels,
the associations were not significant (chi-square, 0.27; p = 0.6 and chi-square, 1.66; p = 0.2,
respectively). Finally, there was a significant relationship between supra-therapeutic
voriconazole and renal toxicity (chi-square, 4.81; p = 0.03).
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Table 6. Adverse events.
Adverse Events Severity a Patients (N = 27), n (%)
Liver abnormalities
ALT
Grade ≥ 1 13/27 (48.2)
Grade ≥ 2 7/27 (25.9)
Grade ≥ 3 1/27 (3.7)
Grade ≥ 4 -
TBIL
Grade ≥ 1 8/27 (29.6)
Grade ≥ 2 6/27 (22.2)
Grade ≥ 3 2/27 (7.4)
Grade ≥ 4 -
ALP
Grade ≥ 1 9/27 (33.3)
Grade ≥ 2 5/27 (18.5)
Grade ≥ 3 1/27 (3.7)
Grade ≥ 4 -
GGT
Grade ≥ 1 22/27 (81.5)
Grade ≥ 2 15/27 (55.6)
Grade ≥ 3 11/27 (40.7)
Grade ≥ 4 6/27 (22.2)
Visual Grade 1 1/27 (3.7)
Neurological/Psychiatric Grade 1 2/27 (7.4)
Gastrointestinal Grade 2 2/27 (7.4)
Skin Grade 2 2/27 (7.4)
Renal Grade 2 1/27 (3.7)
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; TBIL,
total bilirubin. a—Severity of adverse effects according to the Common Terminology Criteria for Adverse Events v5.0
(US Department of Health and Human Services, National Institutes of Health National Cancer Institute).
Multivariate analysis showed no significant associations of any of the variables stud-
ied with plasma voriconazole variability or treatment effectiveness, except a marginally
significant relationship between normal or only slightly elevated CRP and adequate plasma
drug concentrations (MLM, F = 3.22, p = 0.07). There were, however, associations between
hypoalbuminemia and increased TBIL (MLM, F = 4.96, p = 0.03), oral administration and
increased ALT (MLM, F = 4.09, p = 0.04), and a statistical trend to ALT elevation when dual
antifungal therapy was used (MLM, F = 3.75, p = 0.054).
4. Discussion
The findings of this study indicate that voriconazole PC, within the therapeutic range,
are related to treatment effectiveness and safety in children with IFI. In addition, they show
that variability of the drug remains high despite the 2012 updated dosing recommendations,
and that voriconazole levels are influenced by severe hypoalbuminemia and elevated CRP.
Information on voriconazole TDM in children is scarce, particularly in non-Asian
populations and using the new dosage recommendations [31–34,41–43], and the avail-
able data are often heterogeneous and difficult to compare. The main paediatric studies
focussed on plasma voriconazole variability and monitoring published since 2012 are
summarized in Table 7. Most of these studies include a relatively small sample (11 to
74 patients) [17,29,30,32–34,41,44–49]. An exception is the article by Liu et al. [50] with
107 patients (75 younger than 2 y) and the study by Allegra et al. [51] with 237 patients,
although 150 received voriconazole as prophylaxis. As in most of these studies, our sample
is relatively small, but enrolment was prospective and under strict criteria, such as a narrow
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age range and exclusion of patients receiving voriconazole as primary prophylaxis. Our
patient population predominantly included white Europeans (59.3%), with a minority
of Asians (14.8%). It is reported that genetic polymorphisms conditioning voriconazole
metabolism may differ depending on the patients’ ethnicity, and this is especially rele-
vant in Asian patients [27,52–55]. Many of the paediatric studies cited above included a
predominantly Asian population or did not describe the patients’ ethnicity [30,32,41,44–50].
The type of patients and IFIs included here (mainly haematological malignancies and
HSCT, and a predominance of Aspergillus spp.) are consistent with reported
data [17,29,30,32,41,45–49], as are the affected sites and percentage of disseminated in-
fections (28.6%) [10]. The median duration of voriconazole treatment in our study, almost
12 weeks (80.5 days), is longer than values reported in most of the recent paediatric studies,
which range from 23.5 to 72 days [17,29,32,41,45,46,49], although there are some exceptions,
such as the study by Tucker et al. [48] (105 days, 11 patients) and Lempers et al. [33]
(118 days, 21 patients). As was mentioned, our follow-up included voriconazole mainte-
nance treatment; no specific data on this are available in most of the studies cited.
As is seen in Table 7, voriconazole PC often fell outside the therapeutic range. Ade-
quate levels were described in 34% to 50% of patients in older studies using the previous
dosage [17,29,30,44–47,50]. With the new dosing recommendations, our findings indicate
an improvement in this regard. The percentage of patients with therapeutic concentrations
was significantly higher in the present study than our previous one [17] (chi-square, 19.38;
p < 0.01), but voriconazole variability remained high. Of note, some studies have shown
that voriconazole PC are less adequate at the beginning of treatment [33,45], a trend we
also observed. In addition, some authors report the need for higher doses than recom-
mended to achieve optimal levels, especially in younger patients [17,30,33,41,46,49,56],
which agrees with our finding that patients younger than 8 years required a considerably
higher dose than is recommended in the datasheet. According to our data, a maintenance
dose increase that reaches 10 to 11 mg/kg q12h in patients aged 2 to 7 years would lead to
more appropriate voriconazole levels.
Almost two-thirds of inadequate plasma voriconazole values in the present study were
corrected with dose changes. However, sometimes the protocol recommendations were not
strictly followed. In some instances, we found no clinical justification for non-compliance,
but in most cases the PC values were very close to the therapeutic interval and the attending
physician decided to make a smaller dose change than was recommended. Although a
statistically significant difference was not obtained, the percentage of PC correction was
higher when the study recommendations were strictly followed (Figure 1). Other studies
have reported a correction rate of around 60% to 80%, but none of them have described a
predefined scheme for dose adjustment [30,33,41]. Predefined recommendations for adjust-
ing voriconazole dose following monitoring may favour early correction of voriconazole
levels and should be standardized.
Of note, we found that CRP and albumin status had an impact on plasma voriconazole,
with less adequate concentrations in patients with significantly elevated CRP and markedly
decreased albumin. In adults, systemic inflammation has been suggested to play a role in
voriconazole variability [57–64]. To our knowledge, only the studies by ter Avest et al. [65],
Luo et al. [66] and Liu et al. [50] have described a similar impact in paediatric patients.
Our findings indicate that controlling systemic inflammation and optimizing albumin
values could significantly contribute to enhancing the quality of voriconazole treatment in
this population.
As to the effectiveness of voriconazole with the new dosage, our results are similar
or slightly better than those reported in previous paediatric studies [17,29,45,46,48,49].
Nevertheless, it is difficult to perform a direct comparison, as most of these reports did
not use the EORTC/MSG treatment response criteria [39], some included use of the
drug in prophylaxis or in possible IFI, and others excluded deaths not attributable to
IFI [17,29,32,34,41,45,46,48,50].
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Age, Years Initial Dose % PC < 1 mg/L % PC 1–5.5 mg/L % PC > 5.5 mg/L Comments
Soler et al. [17] (2012) 30/196 <18 Lower than 2012recommendations 50% 43% 7%
- Predominance of white Europeans
- Median dose for correct PC in <5 years: 38 mg/kg/day
Pieper et al. [29] (2012) 74/251 <18 Lower than 2012recommendations 57.7% 34.2% 8%
- Predominance of white Europeans
- Therapeutic range considered: 1–5 mg/L
Bartelink et al. [30] (2013) 61/380 <20 Lower than 2012recommendations 1st PC 61% 1st PC 34% 1st PC 5%
- Ethnicity NA (study conducted in The Netherlands)
- Therapeutic range considered: 1–5 mg/L
- Median dose for correct PC in <2 years: 31.5 mg/kg/day
- 80% PC correction when dose adjusted (dose adjustment
recommendation not specified)
Choi et al. [49] (2013) 27/193 <19 Lower than 2012recommendations 31.6% 63.7% 4.7%
- Asian population
- Therapeutic range considered: 1–6 mg/L
- Mean dose for correct PC in ≤6 years: 17.8 mg/kg/day P.O.
Kang et al. [45] (2015) 31/271 <19 Lower than 2012recommendations
1st PC 36.6% - Asian population
- 61 patients, 31 of whom underwent VRC monitoringOverall 29.9% Overall 49.4% Overall 20.7%
Silva et al. [44] (2016) 26/112 2–18 Lower than 2012recommendations 46% 47% 7%
- Ethnicity NA (study conducted in Chile)
- Relationship between IV route and correct PC
Boast et al. [46] (2016) 55/256 <18 Lower than 2012recommendations 44.2% 44.2% 11.7%
- Ethnicity NA (study conducted in Australia)
- Therapeutic range considered: 1–5 mg/L
- Mean dose for correct PC in <6 years: 17.6 mg/kg/day
Kato et al. [47] (2016) 20/111 <18 Lower than 2012recommendations 1st PC 55% NA NA
- Asian population
- Median dose for correct PC in ≤5 years: 13.1 mg/kg/day IV
and 30.1 mg/kg/day P.O.
- Association of sub-therapeutic PCs with oral administration
and younger age
Liu et al. [50] (2017) 107/128 <12 Lower than 2012recommendations 1st PC 48.6% 1st PC 47.7% 1st PC 3.7%
- Asian population
- Relationship between omeprazole and PC elevation
- Relationship between hypoalbuminemia and PC elevation
Martin et al. [32] (2017) 53/NA 2–17 According to 2012recommendations NA NA NA
- 45.3% Asian population (58.1% Asian in IA study)
- Included patients from 2009 to 2013







Age, Years Initial Dose % PC < 1 mg/L % PC 1–5.5 mg/L % PC > 5.5 mg/L Comments
Hu et al. [41] (2018) 42/138 2–14 According to 2012recommendations 1st PC 37.5% 1st PC 50% 1st PC 14.3%
- Asian population
- Mean dose for correct PC: 15.4 mg/kg/day IV and
11.2 mg/kg/day P.O.
- Mean dose for correct PC in <6 years: 22 mg/kg/day P.O.
- 67% PC correction when dose adjusted (dose adjustment
recommendation not specified)
- Association of PC elevation with IV route and PPI
Allegra et al. [51] (2018) 237/NA <18 Lower than 2012recommendations NA NA NA
- Predominance of white Europeans
- 63.5% of patients on VRC prophylaxis
- Relationship between higher serum creatinine and PC elevation
- Relationship between male sex and higher PC
- Positive correlation between age and PC in IV route
Lempers et al. [33] (2019) 21/485 <19
Changes throughout
the study
1st PC 52.4% - Predominance of white Europeans
- Therapeutic range considered: 1–6 mg/L
- Median dose for PC between 1 and4 mg/L in 2–12 years:
24.5 mg/kg/day IV and 25.9 mg/kg/day P.O.
- 60% sub-therapeutic PC corrected and 51% supra-therapeutic
PC corrected when dose adjusted (dose adjustment
recommendation not specified)
Overall 24.1% Overall 58.2% Overall 17.7%
Duehlmeyer et al. [34]
(2021) 45/127 <20
Changes based on
provider and patient NA 45.7% NA
- Predominance of Caucasians
- Included patients from 2010 to 2016
- 53.5% of patients under TDM were on VRC prophylaxis
- Initial dose in prophylaxis lower than 2012 recommendations
- Therapeutic range considered: 2 to 5.5 mg/L for treatment and
>0.5 mg/L for prophylaxis
Valle et al. (2021) 27/229 2–12 According to 2012recommendations
1st PC 37% 1st PC 55.6% 1st PC 7.4% - Predominance of white Europeans
- Median dose for correct PC in ≤7 years: 21 mg/kg/day
- 75% corrected PC when dose adjusted according to protocolled
recommendations
- Association of less adequate VRC PC with elevated CRP and
severe hypoalbuminemia
Overall 27.5% Overall 64.2% Overall8.3%
Abbreviations: CRP, C-reactive protein; IA, invasive aspergillosis; IV, intravenous; NA, information not available; PC, plasma concentrations; P.O., orally; PPI, proton pump inhibitors; TDM, therapeutic drug
monitoring; VRC, voriconazole.
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Figure 1. Voriconazole plasma concentrations (PC) corrections after dose changes according to
protocol compliance.
Dual antifungal therapy was often used in the present study (mainly to cover a
period of possibly inadequate voriconazole PC), but it was of limited duration and not
associated with clinical benefits. Based on our experience, we believe that dual antifungal
therapy use should be limited to the first days of treatment, until voriconazole PC reach
the recommended range.
The relationship between adequate plasma voriconazole levels and treatment ef-
fectiveness can be considered validated in adults [18,22,23,28,67–70], but the evidence
in paediatrics is relatively poor [17,45,49,71]. We found that concentrations higher than
1 mg/L were the only factor related to an improvement in treatment effectiveness at the
later evaluation. To our knowledge, the two studies by our group are the only ones demon-
strating this relationship in non-Asian paediatric patients and using the EORTC/MSG
treatment response criteria.
The available paediatric data on voriconazole safety are heterogeneous, as the cri-
teria for classifying AEs and attributing them to the drug vary widely between studies.
However, the percentage of AEs we detected is similar to the values reported in other
studies using the same AE classification [29,44–46,72]. We mention that our recording
of up to four liver function parameters, including changes with no clinical impact, may
have led to an overestimation of hepatic AEs in our study. Voriconazole-attributed tox-
icity led to discontinuation of the drug in a small number of cases (7.1%), comparable
to the lower range in previous paediatric studies, which report percentages of 3.2% to
26% [29,30,32,41,43,45,48,73]. The relationship between plasma voriconazole levels and
treatment safety has been demonstrated in adults, although there are some inconsisten-
cies regarding the type of AEs and the appropriate cut-off point to indicate a risk of
toxicity [18,22,23,28,68–70]. Again, in paediatrics there is much less evidence in this re-
gard [17,32]. Supra-therapeutic concentrations were associated with neurological and skin
AEs in our previous study [17], and with liver AEs in the study by Martin et al. [32]. We
found a relationship between elevated plasma voriconazole and liver and kidney AEs.
Although the statistical reliability in our analysis of renal AEs was limited by the small
number of cases detected, this association has also been reported by Chu et al. [74] in adults.
The present study has several limitations. First, the relatively small sample size
constrained the statistical power of some analyses, as also occurred in many of the previous
studies. Second, the patients’ high comorbidity and administration of dual antifungal
drugs in some episodes were potential confounding factors when interpreting treatment
safety and effectiveness, also a common point in previous studies. Third, the role of genetic
polymorphisms of cytochrome P450 was not analysed, as no clear recommendations can
be determined on the basis of this finding. Despite these limitations, we believe the study
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provides new data regarding voriconazole use in the treatment of IFI in the paediatric
population that will facilitate comparison with those reported in other studies.
5. Conclusions
Voriconazole at appropriate doses is effective and safe in children. Nonetheless, our
results show that plasma voriconazole variability in paediatric IFI patients remains high
despite the updated dosage recommendations. Higher voriconazole doses are needed in
patients younger than 8 years, and standardized recommendations for dose adjustment
should be designed based on monitoring results. Considering the relationship found
between appropriate PC and voriconazole effectiveness and safety in children, TDM
should be mandatory in this population. In addition to monitoring, efforts should be
intensified to control inflammation, as this factor has an impact on achieving therapeutic
drug levels.
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